

TABLE OF CONTENTS

LIST OF TABLES	xiii
LIST OF FIGURES	xvi
LIST OF ABBREVIATION.....	xvii
CHAPTER 1 INTRODUCTION.....	25
1.1 Introduction.....	26
1.2 Physiology of fibrin formation and its implication in progression of cardiovascular diseases	26
1.3 Cost effectiveness	28
1.4 Side effects.....	28
1.4.1 Depletion of fibrinogen level	28
1.4.2 Hemorrhagic complications	28
1.4.3 Immunological responses.....	29
1.4.4 Different mechanism of action.....	29
1.5 Microbial fibrin(ogen)olytic producing resources	30
1.5.1 Classification of fibrinolytic enzymes	30
1.5.1.1 Direct acting fibrinolytic enzymes	31
1.5.1.1.1 Nattokinase (NK).....	31
1.5.1.2 Indirect acting fibrinolytic enzymes	32
1.5.1.2.1 Streptokinase (SK).....	32
1.5.1.2.2 Staphylokinase (SAK)	33
1.5.1.2.2.1. Mechanism of fibrin selectivity	33
1.5.1.2.3 Urokinase (UK).....	33
1.5.1.2.4 Tissue plasminogen activator (t-PA).....	34
1.5.1.3 Anticoagulant.....	35
1.5.1.3.1 Warfarin	35
1.5.1.3.2 Heparin	35
1.5.1.4 Antiplatelet.....	35
1.6 Aims and objectives of current investigation.....	38
CHAPTER 2 REVIEW OF LITERATURE.....	40
2.1 Sources of fibrin(ogen)olytic enzyme(s).....	41
2.1.1 Fibrinolytic enzymes producing food borne microbes.....	41
2.1.2 Fibrinolytic enzyme producing non-food borne microbes	42
2.2 Identification of fibrin(ogen)olytic enzyme producing microbes by polyphasic approach	44
2.3 Purification and characterization of bacterial fibrin(ogen)olytic enzyme(s) produced by above bacterial strains	45
2.4 Biochemical properties	45
2.4.1 Classification of the fibrin(ogen)olytic enzyme(s) based on catalytic mechanisms.....	46
2.4.1.1. Serine proteases	46
2.4.1.2. Metalloproteases	46
2.4.1.3. Serine and metalloproteases	46
2.4.2 Active site compositions and structural organization of fibrinolytic enzyme	46
2.5 <i>In vitro</i> and <i>in vivo</i> toxicity assessment	50

2.6	Pharmacological applications of isolated fibrin(ogen)olytic enzyme(s) in the treatment of thrombosis under <i>in vivo</i> conditions	51
-----	--	----

CHAPTER 3 MATERIALS AND METHODS.....54

3.1	Materials	55
3.1.1	Columns	55
3.1.2	Chemicals	55
3.1.2.1	Analytical grade	55
3.1.2.2	Microbiological grade culture media/chemicals	56
3.1.2.3	Peptide mass finger printing analysis kit	56
3.1.2.4	Cell lines used cell cytotoxicity study.....	56
3.1.2.5	Serum profiling kits	56
3.2	Methods	57
3.2.1	Collection of fermented food samples	57
3.2.2	Screening of fibrinolytic /fibrin(ogen)olytic enzyme producing bacteria	57
3.2.2.1	Measurement of zone of hydrolysis on fibrin agar plate	57
3.2.2.2	Growth kinetics and fibrinolytic/ fibrin(ogen)olytic protease production.....	57
3.2.2.3	Fibrinolytic to caseinolytic (F/C) ratio.....	58
3.2.2.4	Thrombolytic activity.....	58
3.2.2.5	Substrate specificity	58
3.2.3	Pure culture of fibrinolytic/ fibrin(ogen)olytic protease secreting bacterial isolates	59
3.2.3.1	Spread plate technique	59
3.2.3.2	Streak-plate technique.....	59
3.2.3.3	Routine maintenance and preservation of microorganisms	59
3.2.3.4	Taxonomic identification of fibrinolytic/ fibrin(ogen)olytic producing bacteria	60
3.2.3.5	Morphological tests.....	60
3.2.3.5.1	Simple staining	60
3.2.3.5.2	Negative staining	60
3.2.3.5.3	Gram's staining.....	60
3.2.3.5.4	Spore staining	61
3.2.4	Biochemical tests for strain identification.....	61
3.2.4.1	Hydrolysis test for casein, starch, lipid and gelatin.....	61
3.2.4.2	Carbohydrate fermentation test.....	61
3.2.4.3	Triple sugar iron (TSI) agar test.....	61
3.2.4.4	IMViC test	62
3.2.4.4.1	Indole production test	62
3.2.4.4.2	Methyl red - Voges-Proskauer (MR-VP) test	62
3.2.4.4.3	Citrate Utilization test	62
3.2.4.4.4	Hydrogen sulfide test	62
3.2.4.4.5	Urease test.....	63
3.2.4.4.6	Litmus-milk reactions test.....	63
3.2.4.4.7	Nitrate reduction test.....	63
3.2.4.4.8	Catalase test	63
3.2.4.4.9	Oxidase test.....	63
3.2.5	Identification of bacterial strains.....	64
3.2.5.1	Morphological and biochemical properties.....	64
3.2.5.2	16S rRNA gene sequencing	64
3.2.5.3	PCR amplification of the 16S-23S inter space region (ISR region).....	65
3.2.5.4	Phylogenetic analysis.....	65
3.2.6	Purification of enzymes	66
3.2.6.1	Purification of fibrino(geno)lytic enzyme from <i>Bacillus cereus</i> strain FF01	66

3.2.6.1.1	Step-I: Preparation of cell free crude extract	66
3.2.6.1.2	Step-II: Ammonium sulfate precipitation	66
3.2.6.1.3	Step-III: Hydrophobic interaction chromatography	66
3.2.6.1.4	Step-III: Gel filtration chromatography	66
3.2.6.2	Purification of fibrinolytic enzyme from <i>Brevibacillus brevis</i> strain FF02B.....	67
3.2.6.2.1	Step-I: Preparation of cell free crude extract	67
3.2.6.2.2	Step-II: Hydrophobic interaction chromatography	67
3.2.6.2.3	Step-III: Gel filtration chromatography	67
3.2.7	Biochemical characterization.....	68
3.2.7.1	Determination molecular weight and purity of purified fibrinolytic /fibrin(ogen)olytic enzyme by SDS-PAGE analysis	68
3.2.7.2	Mass spectroscopy	68
3.2.7.3	Fibrin zymography.....	69
3.2.7.4	Fibrinolytic assay	70
3.2.7.5	Fibrin(ogen)olytic assay.....	70
3.2.7.6	Caseinolytic assay	71
3.2.7.7	Protein estimation	71
3.2.7.8	Substrate specificity of purified enzyme	71
3.2.7.9	Determination of amidolytic activity	71
3.2.7.10	Effect of pH on fibrin(ogen)olytic / fibrinolytic activity and stability	72
3.2.7.11	Determination of optimum temperature for protease activity	72
3.2.7.12	Effect of protease inhibitors and metal ions	73
3.2.7.13	Determination of plasminogen activating assay.....	73
3.2.7.14	Determination of carbohydrate content.....	73
3.2.7.15	Determination of glycosylation on purified enzymes	74
3.2.8	Biophysical characterization	74
3.2.8.1	Fluorescence spectroscopy.....	74
3.2.8.2	Peptide mass finger printing analysis.....	75
3.2.8.3	Amino acids composition analysis.....	75
3.2.9	Secondary structure determination.....	76
3.2.10	Pharmacological characterization	76
3.2.10.1	Hemolytic assay	76
3.2.10.2	Anticoagulant assay	77
3.2.10.3	Thrombolytic assay.....	77
3.2.11	Cell cytotoxicity assay	77
3.2.12	Assay of thrombin and FXa inhibition.....	78
3.2.13	Platelet modulating activity of purified fibrinolytic/ fibrin(ogen)olytic enzyme	79
3.2.14	Determination of antagonistic effect of purified fibrinolytic enzyme / fibrin(ogen)olytic enzyme on collagen and ADP-induced aggregation of PRP	80
3.2.15	<i>In vivo</i> lethality and toxicity	80
3.2.15.1	Electrocardiograms (ECG) and whole body plethysmograph.....	81
3.2.15.2	Hematological parameters and serum biochemical profiles.....	82
3.2.15.3	Histopathological study	83
3.2.16	Evaluation of <i>in vivo</i> thrombolytic potential of purified fibrinolytic / fibrin(ogen)olytic enzyme in rat model.....	84
3.2.16.1	Carrageenan induced thrombus induction in rat model	84
3.2.16.2	<i>In vivo</i> thrombolytic activity	85
3.2.16.3	Coagulation assay	86
3.2.16.3.1	Determination of activated partial thromboplastin time (APTT).....	86
3.2.16.3.2	Determination of prothrombin time (PT).....	86
3.2.16.3.3	Determination of thrombin time (TT).....	87
3.2.16.3.4	Determination of fibrinogen (Fg).....	87

3.2.16.3.5	Determination of Ca ⁺² -clotting time	87
3.2.17	Statistical analysis.....	88
CHAPTER 4 RESULTS AND DISCUSSION.....		89
4.1	Brief introduction.....	90
4.2	Results.....	91
4.2.1	Screening and isolation of fibrin(ogen)olytic enzyme producing bacteria.....	91
4.2.2	Taxonomic identification of fibrin(ogen)olytic enzyme producing bacterial strain FF01	93
4.2.2.1	Morphological and biochemical study of fibrin(ogen)olytic enzyme producing bacterial isolates	93
4.2.2.2	Phylogenetic analysis of bacterial isolates based on 16S rDNA sequencing	95
4.2.2.3	Phylogeny of strain FF01	97
4.2.2.4	Phylogenetic analysis of bacterial isolates based on 16S-23S ISR sequences	98
4.2.2.5	Phylogenetic analysis of isolated strain FF01	99
4.2.2.6	Purification of a fibrin(ogen)olytic enzyme from <i>Bacillus cereus</i> strain FF01.....	100
4.2.2.7	Identification of Bacethrombase by N terminal sequencing, peptide mass fingerprinting and amino acid composition analyses.....	103
4.2.2.8	Secondary structure of Bacethrombase	105
4.2.2.9	Amidolytic activity of Bacethrombase	105
4.2.2.10	Determination of <i>K_m</i> and <i>V_{max}</i> of Bacethrombase and plasmin.....	106
4.2.2.11	Effect of Bacethrombase on extracellular membrane protein hydrolysis.....	107
4.2.2.12	Biochemical properties of Bacethrombase.....	108
4.2.2.12.1	Effect of temperature on activity of Bacethrombase.....	108
4.2.2.12.2	Effect of pH on activity of Bacethrombase	109
4.2.2.12.3	Plasminogen activation property of Bacethrombase	111
4.2.2.12.4	Inhibitory activity of Bacethrombase.....	112
4.2.2.12.5	Glycosylation on Bacethrombase.....	113
4.2.2.12.5.1	Total neutral carbohydrate content Bacethrombase	113
4.2.2.12.5.2	Sialic acid content of Bacethrombase	113
4.2.2.12.5.3	Kinetics of fibrin degradation by Bacethrombase	114
4.2.2.13	Pharmacological properties of Bacethrombase	117
4.2.2.13.1	<i>In-vitro</i> thrombolytic activity of Bacethrombase	117
4.2.2.13.2	Cell cytotoxicity and hemolytic activity of Bacethrombase	118
4.2.2.13.3	Antiplatelet activity of Bacethrombase	119
4.2.2.13.3.1	Effect of Bacethrombase on platelet aggregation	119
4.2.2.13.3.2	Effect of Bacethrombase on collagen-induced platelet aggregation	120
4.2.2.13.3.3	Determination of IC ₅₀ value of Bacethrombase from the regression analysis of inhibition curve	121
4.2.2.13.4	Anticoagulant property of Bacethrombase.....	122
4.2.2.13.4.1	Effect of Bacethrombase on recalcification time of PPP	122
4.2.2.13.4.2	Comparison of anticoagulant activity of Bacethrombase with commercial anticoagulant	123
4.2.2.13.4.3	Mechanism of anticoagulant action by Bacethrombase	124
4.2.2.13.4.3.1	Effect on thrombin and FXa inhibition by Bacethrombase	124
4.2.2.13.4.3.2	Interaction study between Bacethrombase and fibrinogen/thrombin by spectrofluorometer	125
4.2.2.13.4.3.3	Inhibition of thrombin.....	126
4.2.2.13.5	Evaluation of <i>in vivo</i> toxicity of Bacethrombase in a rat model	127
4.2.2.13.5.1	Physiological changes after Bacethrombase administration in rats	127
4.2.2.13.5.2	Effect of Bacethrombase on hematological parameters in rats	130
4.2.2.13.5.3	Effect of Bacethrombase on biochemical parameters of serum of treated rat.....	131

4.2.2.13.5.4	Evaluation of Histopathology	131
4.2.2.13.5.5	<i>In vivo</i> thrombolytic potency of Bacethrombase.....	133
4.2.2.13.5.5.1	Thrombus induction in rat tail with optimized dose of carrageenan.....	133
4.2.2.13.5.5.2	<i>In vivo</i> thrombolytic potency of Bacethrombase	134
4.2.2.14	Anticoagulant potency of Bacethrombase <i>in vivo</i> condition.....	135
4.2.2.14.1	Dose-dependent activated partial thromboplastin time (APTT) and prothrombin time (PT) of Bacethrombase	135
4.2.2.14.2	<i>In vivo</i> effect of Bacethrombase on thrombin time (TT) of rat plasma.....	136
4.2.2.14.3	<i>In vivo</i> dose-dependent fibrin(ogen)olytic activity of Bacethrombase.....	137
4.2.2.14.4	<i>In vivo</i> anticoagulant activity of Bacethrombase	138
4.3	Discussion.....	139

CHAPTER 5 RESULTS AND DISCUSSION.....143

5.1	Brief introduction.....	144
5.2	Results.....	145
5.2.1	Screening and isolation of fibrinolytic enzyme producing bacteria:	145
5.2.2	Taxonomic identification of fibrinolytic enzyme producing strain FF02B.....	147
5.2.2.1	Biochemical and morphological study of fibrinolytic enzyme producing bacterial isolate	147
5.2.2.2	Phylogenetic analysis of isolated strain FF02B	148
5.2.2.3	Phylogenetic analysis of isolated strain FF02B	153
5.3	Purification of a major fibrinolytic enzyme	154
5.4	Identification of Brevithrombolase by N-terminal sequencing, peptide mass fingerprinting and amino acid composition analysis.....	157
5.5	Secondary structure of Brevithrombolase	158
5.6	Amidolytic activity of Brevithrombolase.....	159
5.7	Biochemical properties of Brevithrombolase.....	160
5.7.1	Effect of temperature on activity of Brevithrombolase.....	160
5.7.2	Effect of pH on activity of Brevithrombolase.....	161
5.7.3	Substrate specificity	162
5.7.4	Plasminogen activation property.....	162
5.7.5	Inhibition studies of Brevithrombolase	163
5.7.6	Glycosylation on Brevithrombolase.....	163
5.7.6.1	Sialic acids residues in Brevithrombolase.....	163
5.7.7	Kinetics of fibrin degradation by Brevithrombolase	164
5.8	Pharmacological properties of Brevithrombolase	167
5.8.1	Thrombolytic activity of Brevithrombolase	167
5.8.2	Cell cytotoxicity and hemolytic activity of Brevithrombolase	168
5.8.3	Anticoagulant property of Brevithrombolase.....	168
5.8.3.1	Comparison of anticoagulant activity of Brevithrombolase with commercial anticoagulant	168
5.8.3.2	Effect of Brevithrombolase on recalcification time of PPP.	169
5.8.4	Anticoagulant mechanism of Brevithrombolase	170
5.8.4.1	Thrombin and FXa inhibitory activity	170
5.8.4.2	Analysis of interaction between thrombin and Brevithrombolase by spectrofluorometric study.....	173
5.8.4.3	Thrombin degradation property of Brevithrombolase	174
5.9	<i>In vivo</i> toxicity in rats	174
5.9.1	Physiological changes after Brevithrombolase administration in rats	174
5.9.2	Effect of Brevithrombolase on hematological parameters of rats	175
5.9.3	Biochemical changes in serum profile after Brevithrombolase administration in rats.	177
5.9.4	Histopathological examination of tissues from Brevithrombolase-treated rat	177

5.10	Effect on tail bleeding and clotting time of rat after Brevithrombolase administration	179
5.11	<i>In vivo</i> thrombolytic activity of Brevithrombolase	179
5.12	Anticoagulant activity of Brevithrombolase in <i>in vivo</i> condition	181
5.12.1	Dose-dependent activated partial thromboplastin time (APTT) and prothrombin time (PT) of Brevithrombolase	181
5.12.2	Dose-dependent thrombin time (TT) of Brevithrombolase-treated rats.....	182
5.12.3	<i>In vivo</i> dose-dependent fibrinogenolytic activity of Brevithrombolase	183
5.12.4	<i>In vivo</i> recalcification time of Brevithrombolase.....	184
5.13	Discussion.....	185
CONCLUSION.....		192
REFERENCE.....		194
APPENDIX I		212
APPENDIX II.....		219